[ad_1]
The Indian Council of Medical Research (ICMR) and Panacea Biotec Limited on Wednesday announced the launch of India’s first Phase 3 clinical trial for a dengue vaccine.
The trial will evaluate the effectiveness of India’s indigenous quadrivalent dengue vaccine DengiAll, developed by Panacea Biotec. The first participant of the trial was vaccinated on Wednesday at the Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences in Rohtak.
The quadrivalent dengue vaccine strain (TV003/TV005) developed by the National Institutes of Health has shown good results in preclinical and clinical trials around the world. (Foreign institutions)
Posts India launches first dengue vaccine phase III clinical trial First appeared in Daily News.
[ad_2]
Source link
